Cyr61/CCN1 Antibody [DyLight 550]

Immunocytochemistry/Immunofluorescence: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ICC/IF staining of 3 tissue arrays with 104 invasive ductal carcinoma tissue sections with metastatic carcinomas, 21 invasive ductal carcinoma tissue sections, & 8 normal tissue sections. 33 carcinoma tissue sections were -ve for estrogen & progesterone receptor; don't overexpress Her2neu receptor (triple negative breast cancer, TNBC). (A) Cyr61/CCN1 and/or S100A4 expression analysis in 123 invasive ductal carcinoma tissue & lymph node sections of 104 patients (B); representative ICC/IF stains analyzed with 100x oil objective. (C) From 123 invasive ductal carcinomas tissue sections, 33 stated as being TNBC. (D) Normal breast tissue sections (n = 8) analyzed for Cyr61/CCN1 and/ or S100A4 expression using ICC/IF. Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (https://www.frontiersin.org/article/10.3389/fonc.2019.01074/full), licensed under a CC-BY license.

Western Blot: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] -

Western Blot: Cyr61/CCN1 Antibody [DyLight 550] [NB100-356R] - ERK1/2 activity is transducer of CYR61 mediated S100A4 regulation. (A) Scheme illustrating hypothesis of CYR61 regulating S100A4 in a p-ERK1/2 dependent manner. (B) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) expression in different breast cancer cell lines detected by western blotting. (C) ERK1/2 & p-Erk1/2 (Thr202/Tyr204) & CYR61 expression in different breast cancer cell lines after transient CYR61 transfection detected by western blotting. (D) Relative S100A4 expression of invasive breast cancer cell lines treated with 10 μM U0126 compared to DMSO controls. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. n = 3; *P < 0.05;**P < 0.01;***P < 0.005 (E) 3D invasion analysis of breast cancer spheroids seeded after U0126 treatment. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection & compared to spheroid area at time point 0 (adding of Matrigel + 10 μM U0126). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t-test analysis. MCF-7-EMT n = 6; T47D-EMT n = 5; MDA-MB-231 n = 6; HCC1806 n = 5; **P < 0.01;***P < 0.005;****P < 0.0001 (F) Analysis of relative AlamarBlue reduction as indicator for cell viability. Breast cancer cell spheroids were grown & AlamarBlue reduction was assessed 48 h after adding Matrigel & 10 μM U0126 at 4 h incubation. Relative AlamarBlue reduction was calculated compared to DMSO control spheroids. Data represent mean ± SEM. MCF-7-EMT n = 3; T47D-EMT n = 4; MDA-MB-231 n = 3; HCC1806 n = 3; *P < 0.05;**P < 0.01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31709177), licensed under a CC-BY license. Not internally tested by Novus Biologicals.